{\rtf1\deflang1033\deflangfe1033\margl720\margr720\margt360\margb360{\stylesheet{\fs20\lang1033\snext0 Normal;} {\s1\sb240\keepn{\*\pn \pnlvl1\pndec\pnprev1\pnstart1\pnsp144}\b\f0\fs30\lang1033 \sbasedon0\snext0 heading 1;} {\s2\sb200\keepn{\*\pn \pnlvl2\pndec\pnprev1\pnstart1\pnsp144{\pntxtb.}}\b\f0\fs26\lang1033 \sbasedon0\snext0 heading 2;} {\s3\sb180\keepn{\*\pn \pnlvl3\pndec\pnprev1\pnstart1\pnsp144{\pntxtb.}}\b\f0\fs22\lang1033 \sbasedon0\snext0 heading 3;} {\s4\sb160\keepn{\*\pn \pnlvl4\pnucltr\pnprev1\pnstart1\pnsp144{\pntxtb.}}\b\f0\fs22\lang1033 \sbasedon0\snext0 heading 4;} {\s5\sb140\keepn{\*\pn \pnlvl5\pncltr\pnprev1\pnstart1\pnsp144}\b\f0\fs20\lang1033 \sbasedon0\snext0 heading 5;} {\s6\tqc\lang1033\sbasedon0\snext6 footer;} {\*\cs16 \additive\super\sbasedon10 footnote reference;} {\*\cs18 \additive\sbasedon10 page number;}} {\fonttbl{\f0\fnil Times New Roman;}{\f1\fnil Courier New}{\f2005\fnil Courier New;}{\f2010\fnil Wingdings;}{\f2020\fnil Webdings;}{\f2\fnil Arial;}{\f3\fnil Arial;}{\f4\fnil LucidaHandwriting;}{\f5\fnil Symbol;}{\f6\fnil Symbol;}{\f7\fnil Ferdsch;}{\f30\fnil Myriad Cn Semibold;}{\f31\fnil Myriad Roman;}{\f50\fnil Courier New;}{\f51\fnil Times New Roman;}{\f52\fnil Arial;}{\f53\fnil Symbol;}{\f54\fnil Wingdings;}{\f55\fnil Wingdings 2;}{\f56\fnil Wingdings 3;}{\f57\fnil Webdings;}{\f58\fnil Arial Narrow;}{\f59\fnil Arial Unicode MS;}{\f60\fnil Cyberbit;}{\f61\fnil Morningstar 1U Light;}{\f62\fnil Calibri;}} {\colortbl;\red0\green0\blue0;\red127\green0\blue0;\red0\green0\blue255;\red127\green127\blue127;\red0\green51\blue153;\red255\green204\blue0;\red255\green255\blue255;\red246\green244\blue236;\red0\green0\blue0;} {\*\bkmkstart filing_1}{\*\bkmkend filing_1}{\*\bkmkstart doc_1_1}{\*\bkmkend doc_1_1}\par\pard\plain\f0\fs16\par\pard\plain\cf1\f50\fs16\ql SCHEDULE 13G \par\pard\plain\fs16 \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql Amendment No. 6 \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql THERAPEUTICSMD INC \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql COMMON STOCK \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql Cusip #88338N107 \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql Check the appropriate box to designate the rule pursuant to which this \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql Schedule is filed: \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql [x] Rule 13d-1(b) \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql [ ] Rule 13d-1(c) \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql [ ] Rule 13d-1(d) \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql Cusip #88338N107 \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql Item 1: Reporting Person - FMR LLC \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql Item 2: (a) [ ] \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql (b) [ ] \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql Item 4: Delaware \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql Item 5: 883,700 \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql Item 6: 0 \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql Item 7: 23,068,840 \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql Item 8: 0 \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql Item 9: 23,068,840 \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql Item 11: 10.658% \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql Item 12: HC \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql Cusip #88338N107 \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql Item 1: Reporting Person - Abigail P. Johnson \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql Item 2: (a) [ ] \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql (b) [ ] \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql Item 4: United States of America \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql Item 5: 0 \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql Item 6: 0 \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql Item 7: 23,068,840 \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql Item 8: 0 \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql Item 9: 23,068,840 \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql Item 11: 10.658% \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql Item 12: IN \par\pard\plain\fs16 \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql Item 1(a). Name of Issuer: \par\pard\plain\fs16 \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql THERAPEUTICSMD INC \par\pard\plain\fs16 \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql Item 1(b). Address of Issuer's Principal Executive Offices: \par\pard\plain\fs16 \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql 6800 BROKEN SOUND PARKWAY NW \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql Third Floor \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql BOCA RATON, FL 33487 \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql USA \par\pard\plain\fs16 \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql Item 2(a). Name of Person Filing: \par\pard\plain\fs16 \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql FMR LLC \par\pard\plain\fs16 \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql Item 2(b). Address or Principal Business Office or, if None, \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql Residence: \par\pard\plain\fs16 \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql 245 Summer Street, Boston, Massachusetts 02210 \par\pard\plain\fs16 \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql Item 2(c). Citizenship: \par\pard\plain\fs16 \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql Not applicable \par\pard\plain\fs16 \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql Item 2(d). Title of Class of Securities: \par\pard\plain\fs16 \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql COMMON STOCK \par\pard\plain\fs16 \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql Item 2(e). CUSIP Number: \par\pard\plain\fs16 \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql 88338N107 \par\pard\plain\fs16 \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql or (c) and the \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql person filing, FMR LLC, is a parent holding company in accordance with \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql Section 240.13d-1(b)(1)(ii)(G). (Note: See Exhibit A). \par\pard\plain\fs16 \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql Item 4. Ownership \par\pard\plain\fs16 \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql (a) Amount Beneficially Owned: 23,068,840 \par\pard\plain\fs16 \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql (b) Percent of Class: 10.658% \par\pard\plain\fs16 \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql (c) Number of shares as to which such person has: \par\pard\plain\fs16 \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql (i) sole power to vote or to direct the vote: \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql 883,700 \par\pard\plain\fs16 \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql (ii) shared power to vote or to direct the vote: 0 \par\pard\plain\fs16 \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql (iii) sole power to dispose or to direct the \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql disposition of: 23,068,840 \par\pard\plain\fs16 \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql (iv) shared power to dispose or to direct the \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql disposition of: 0 \par\pard\plain\fs16 \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql Item 5. Ownership of Five Percent or Less of a Class. \par\pard\plain\fs16 \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql Not applicable. \par\pard\plain\fs16 \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql Item 6. Ownership of More than Five Percent on Behalf of Another \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql Person. \par\pard\plain\fs16 \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql One or more other persons are known to have the right to receive or the \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql power to direct the receipt of dividends from, or the proceeds from the \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql sale of, the COMMON STOCK of THERAPEUTICSMD INC. No one other person's \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql interest in the COMMON STOCK of THERAPEUTICSMD INC is more than five \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql percent of the total outstanding COMMON STOCK. \par\pard\plain\fs16 \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql Item 7. Identification and Classification of the Subsidiary Which \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql Acquired the Security Being Reported on By the Parent Holding Company. \par\pard\plain\fs16 \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql See attached Exhibit A. \par\pard\plain\fs16 \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql Item 8. Identification and Classification of Members of the Group. \par\pard\plain\fs16 \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql Not applicable. \par\pard\plain\fs16 \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql Item 9. Notice of Dissolution of Group. \par\pard\plain\fs16 \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql Not applicable. \par\pard\plain\fs16 \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql Item 10. Certifications. \par\pard\plain\fs16 \par\pard\plain\fs16 \par\pard\plain\fs16 \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql By signing below I certify that, to the best of my knowledge and belief, \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql the securities referred to above were acquired and are held in the ordinary \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql course of business and were not acquired and are not held for the purpose \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql of or with the effect of changing or influencing the control of the issuer \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql of the securities and were not acquired and are not held in connection with \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql or as a participant in any transaction having that purpose or effect. \par\pard\plain\fs16 \par\pard\plain\fs16 \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql Signature \par\pard\plain\fs16 \par\pard\plain\fs16 \par\pard\plain\fs16 \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql After reasonable inquiry and to the best of my knowledge and belief, I \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql certify that the information set forth in this statement is true, complete \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql and correct. \par\pard\plain\fs16 \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql February 13, 2018 \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql Date \par\pard\plain\fs16 \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql /s/ Marc R. Bryant \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql Signature \par\pard\plain\fs16 \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql Marc R. Bryant \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql Duly authorized under Power of Attorney effective as of September 23, \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql 2015, by and on behalf of FMR LLC and its direct and indirect subsidiaries* \par\pard\plain\fs16 \par\pard\plain\fs16 \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql * This power of attorney is incorporated herein by reference to Exhibit 24 \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql to the Schedule 13G filed by FMR LLC on June 10, 2016, accession number: \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql 0000315066-16-005935 \par\pard\plain\fs16 \par\pard\plain\fs16 \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql Exhibit A \par\pard\plain\fs16 \par\pard\plain\fs16 \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql Pursuant to the instructions in Item 7 of Schedule 13G, \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql the following table lists the identity and Item 3 classification, if \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql applicable, of each relevant entity that beneficially owns shares of the \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql security class being reported on this Schedule 13G. \par\pard\plain\fs16 \par\pard\plain\fs16 \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql Entity ITEM 3 Classification \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql FIAM LLC IA \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql Fidelity Institutional Asset Management Trust Company BK \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql FMR CO., INC * IA \par\pard\plain\fs16 \par\pard\plain\fs16 \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql * Entity beneficially owns 5% or greater of the outstanding shares of the \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql security class being reported on this Schedule 13G. \par\pard\plain\fs16 \par\pard\plain\fs16 \par\pard\plain\fs16 \par\pard\plain\fs16 \par\pard\plain\fs16 \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql Abigail P. Johnson is a Director, the Chairman and the \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql Chief Executive Officer of FMR LLC. \par\pard\plain\fs16 \par\pard\plain\fs16 \par\pard\plain\fs16 \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql Members of the Johnson family, including Abigail P. \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql Johnson, are the predominant owners, directly or through trusts, of Series \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql B voting common shares of FMR LLC, representing 49% of the voting power of \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql FMR LLC. The Johnson family group and all other Series B shareholders have \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql entered into a shareholders' voting agreement under which all Series B \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql voting common shares will be voted in accordance with the majority vote of \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql Series B voting common shares. Accordingly, through their ownership of \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql voting common shares and the execution of the shareholders' voting \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql agreement, members of the Johnson family may be deemed, under the \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql Investment Company Act of 1940, to form a controlling group with respect to \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql FMR LLC. \par\pard\plain\fs16 \par\pard\plain\fs16 \par\pard\plain\fs16 \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql Neither FMR LLC nor Abigail P. Johnson has the sole power \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql to vote or direct the voting of the shares owned directly by the various \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql investment companies registered under the Investment Company Act ("Fidelity \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql Funds") advised by Fidelity Management & Research Company ("FMR Co"), a \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql wholly owned subsidiary of FMR LLC, which power resides with the Fidelity \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql Funds' Boards of Trustees. Fidelity Management & Research Company carries \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql out the voting of the shares under written guidelines established by the \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql Fidelity Funds' Boards of Trustees. \par\pard\plain\fs16 \par\pard\plain\fs16 \par\pard\plain\fs16 \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql This filing reflects the securities beneficially owned, or \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql that may be deemed to be beneficially owned, by FMR LLC, certain of its \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql subsidiaries and affiliates, and other companies (collectively, the "FMR \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql Reporters"). This filing does not reflect securities, if any, beneficially \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql owned by certain other companies whose beneficial ownership of securities \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql is disaggregated from that of the FMR Reporters in accordance with \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql Securities and Exchange Commission Release No. 34-39538 (January 12, 1998). \par\pard\plain\fs16 \par\pard\plain\fs16 \par\pard\plain\fs16 \par\pard\plain\fs16 \par\pard\plain\fs16 \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql RULE 13d-1(k)(1) AGREEMENT \par\pard\plain\fs16 \par\pard\plain\fs16 \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql The undersigned persons, on February 13, 2018, agree and \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql consent to the joint filing on their behalf of this Schedule 13G in \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql connection with their beneficial ownership of the COMMON STOCK of \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql THERAPEUTICSMD INC at December 29, 2017. \par\pard\plain\fs16 \par\pard\plain\fs16 \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql FMR LLC \par\pard\plain\fs16 \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql By /s/ Marc R. Bryant \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql Marc R. Bryant \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql Duly authorized under Power of Attorney effective as of September 23, \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql 2015, by and on behalf of FMR LLC and its direct and indirect subsidiaries* \par\pard\plain\fs16 \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql Abigail P. Johnson \par\pard\plain\fs16 \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql By /s/ Marc R. Bryant \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql Marc R. Bryant \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql Duly authorized under Power of Attorney effective as of December 16, \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql 2015, by and on behalf of Abigail P. Johnson* \par\pard\plain\fs16 \par\pard\plain\fs16 \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql * This power of attorney is incorporated herein by reference to Exhibit 24 \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql to the Schedule 13G filed by FMR LLC on June 10, 2016, accession number: \par\pard\plain\fs16\pard\plain\cf1\f50\fs16\ql 0000315066-16-005935 \par\pard\plain\fs16 \par\pard\plain\fs16 \par\pard\plain\fs16 \par\pard\plain\fs16}